Sankt Eriksgatan 117
About Modus TherapeuticsModus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
CEO: Christina Herder
Please click here for Modus job opportunities.
Tweets by Modus
8 articles with Modus Therapeutics
Modus Therapeutics Completes Enrollment of its Randomized, Placebo-Controlled Phase II Clinical Trial Evaluating Sevuparin for the Management of Acute Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease
Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has completed patient enrollment in its Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Sevuparin Infusion for the Management of Acute
Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease
Modus Therapeutics AB announces that the FDA has accepted its sevuparin IND for the treatment of SCD.
Modus Therapeutics today announces that CEO Ellen K. Donnelly will present at the 10th Annual Biotech Showcase held in San Francisco from January 8 - 10, 2018.
Karolinska Development AB Company Modus To Present Poster At 58th American Society of Hematology Annual Meeting In San Diego